Form D · Biotechnology
Elucida Oncology, Inc.
Monmouth Junction, NJ · CIK 0001704594
Offering snapshot reported Aug 3, 2023 · SEC filing
- Reported sold
- $22.3M Offering amount: $22.3M
- Investors reported
- 107 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 24, 2023 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$22,936,960 → $22,284,600
- Reported investors277 → 107
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 3, 2023 | Amendment | $22,284,600 | -$652,360vs Jun 15, 2023 | 107 | SEC filing |
| Jun 15, 2023 | Initial | $22,936,960 | No comparison | 277 | SEC filing |
| Mar 28, 2022 | Initial | $22,284,600 | No comparison | 107 | SEC filing |
| Jan 12, 2021 | Amendment | $35,000,000 | $17,306,882vs Nov 10, 2020 | 328 | SEC filing |
| Dec 29, 2020 | Amendment | $32,552,878 | $14,859,760vs Nov 10, 2020 | 303 | SEC filing |
| Dec 10, 2020 | Amendment | $27,236,639 | $9,543,521vs Nov 10, 2020 | 149 | SEC filing |
| Nov 10, 2020 | Initial | $17,693,118 | No comparison | 149 | SEC filing |
| Jun 4, 2020 | Amendment | $8,782,683 | $1,392,898vs May 26, 2020 | 126 | SEC filing |
| May 26, 2020 | Initial | $7,389,785 | No comparison | 104 | SEC filing |
| Feb 7, 2019 | Amendment | $28,759,605 | $17,900,356vs Aug 22, 2017 | 175 | SEC filing |
| Jan 3, 2019 | Amendment | $28,094,604 | $17,235,355vs Aug 22, 2017 | 170 | SEC filing |
| Aug 22, 2017 | Initial | $10,859,249 | No comparison | 94 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.23M
- Finders' fees
- $0
- Form D file number
- 021-484316
In addition, the Company issued the Placement Agent Warrants to purchase 526,316 shares of Common Stock of Elucida in connection with the offering.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Maxim Group LLC | 120708 |
Source: Form D, filed Aug 3, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gregory Adams | Executive |
| Eliel Bayever | Executive |
| Isaac Blech | Director |
| Tim Boris | Director |
| Michelle Bradbury | Director |
| Robert Essner | Director, Executive |
| Geno Germano | Director, Executive |
| Somaiya Ian | Executive |
| Steven Larson | Director |
| Kai Ma | Executive |
| Natalie Mac Donald | Director |
| Sigurdur Olafsson | Director |
| Teresa Ressel | Director |
| Edward Rosen | Director, Executive |
| Robert Ruffolo | Director |
| Gary Sender | Director |
| Michael Smith | Director |
| Ulrich Wiesner | Director |
| David Zacardelli | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Deer Park Drive
Monmouth Junction, NJ, 08852
Monmouth Junction, NJ, 08852